Medical - Devices
Compare Stocks
4 / 10Stock Comparison
HSDT vs DBVT vs ALKS vs STIM
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Medical - Diagnostics & Research
HSDT vs DBVT vs ALKS vs STIM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Devices | Biotechnology | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $89M | $1690.08T | $5.83B | $115M |
| Revenue (TTM) | $6M | $0.00 | $1.56B | $152M |
| Net Income (TTM) | $-41M | $-168M | $153M | $-37M |
| Gross Margin | 91.7% | — | 65.4% | 48.0% |
| Operating Margin | -351.0% | — | 12.3% | -19.4% |
| Forward P/E | — | — | 24.5x | — |
| Total Debt | $0.00 | $22M | $70M | $90M |
| Cash & Equiv. | $7M | $194M | $1.12B | $34M |
HSDT vs DBVT vs ALKS vs STIM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Solana Company (HSDT) | 100 | 0.0 | -100.0% |
| DBV Technologies S.… (DBVT) | 100 | 40.7 | -59.3% |
| Alkermes plc (ALKS) | 100 | 213.9 | +113.9% |
| Neuronetics, Inc. (STIM) | 100 | 90.4 | -9.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HSDT vs DBVT vs ALKS vs STIM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
HSDT is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 10.6%, EPS growth 57.3%, 3Y rev CAGR 97.0%
- 10.6% revenue growth vs DBVT's -100.0%
DBVT is the clearest fit if your priority is income & stability.
- Dividend streak 0 yrs, beta 1.26
- +100.5% vs HSDT's -99.0%
ALKS carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- -12.0% 10Y total return vs DBVT's -87.1%
- Lower volatility, beta 1.00, Low D/E 3.8%, current ratio 3.55x
- Beta 1.00, current ratio 3.55x
- 9.8% margin vs HSDT's -6.8%
STIM lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 10.6% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 9.8% margin vs HSDT's -6.8% | |
| Stability / Safety | Beta 1.00 vs HSDT's 2.65 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +100.5% vs HSDT's -99.0% | |
| Efficiency (ROA) | 5.4% ROA vs DBVT's -89.0% |
HSDT vs DBVT vs ALKS vs STIM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
HSDT vs DBVT vs ALKS vs STIM — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 2 of 6 categories
STIM leads 1 • HSDT leads 0 • DBVT leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — HSDT and ALKS each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to HSDT's -6.8%. On growth, HSDT holds the edge at +33.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $6M | $0 | $1.6B | $152M |
| EBITDAEarnings before interest/tax | -$21M | -$112M | $212M | -$27M |
| Net IncomeAfter-tax profit | -$41M | -$168M | $153M | -$37M |
| Free Cash FlowCash after capex | -$17M | -$151M | $392M | -$4M |
| Gross MarginGross profit ÷ Revenue | +91.7% | — | +65.4% | +48.0% |
| Operating MarginEBIT ÷ Revenue | -3.5% | — | +12.3% | -19.4% |
| Net MarginNet income ÷ Revenue | -6.8% | — | +9.8% | -24.5% |
| FCF MarginFCF ÷ Revenue | -2.7% | — | +25.1% | -2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +33.4% | — | +28.2% | +7.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.9% | +91.5% | -4.1% | +23.8% |
Valuation Metrics
STIM leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $89M | $1690.08T | $5.8B | $115M |
| Enterprise ValueMkt cap + debt − cash | $82M | $1690.08T | $4.8B | $171M |
| Trailing P/EPrice ÷ TTM EPS | -1.20x | -0.75x | 24.47x | -2.81x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 17.01x | — |
| Price / SalesMarket cap ÷ Revenue | 14.87x | — | 3.95x | 0.77x |
| Price / BookPrice ÷ Book value/share | 0.16x | 0.65x | 3.25x | 4.16x |
| Price / FCFMarket cap ÷ FCF | — | — | 12.14x | — |
Profitability & Efficiency
ALKS leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-140 for STIM. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to STIM's 3.44x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs STIM's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -105.0% | -130.2% | +8.8% | -139.8% |
| ROA (TTM)Return on assets | -20.7% | -89.0% | +5.4% | -27.1% |
| ROICReturn on invested capital | -10.8% | — | +18.9% | -26.6% |
| ROCEReturn on capital employed | -14.0% | -145.7% | +14.2% | -28.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 7 | 4 |
| Debt / EquityFinancial leverage | — | 0.13x | 0.04x | 3.44x |
| Net DebtTotal debt minus cash | -$7M | -$172M | -$1.0B | $56M |
| Cash & Equiv.Liquid assets | $7M | $194M | $1.1B | $34M |
| Total DebtShort + long-term debt | $0 | $22M | $70M | $90M |
| Interest CoverageEBIT ÷ Interest expense | -63.39x | -189.82x | 32.30x | -2.43x |
Total Returns (Dividends Reinvested)
Evenly matched — DBVT and ALKS each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,165 today (with dividends reinvested), compared to $0 for HSDT. Over the past 12 months, DBVT leads with a +100.5% total return vs HSDT's -99.0%. The 3-year compound annual growth rate (CAGR) favors DBVT at 5.7% vs HSDT's -92.8% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -28.2% | +3.6% | +23.8% | +14.9% |
| 1-Year ReturnPast 12 months | -99.0% | +100.5% | +15.2% | -64.4% |
| 3-Year ReturnCumulative with dividends | -100.0% | +18.1% | +13.2% | -24.8% |
| 5-Year ReturnCumulative with dividends | -100.0% | -68.3% | +61.7% | -87.3% |
| 10-Year ReturnCumulative with dividends | -100.0% | -87.1% | -12.0% | -94.0% |
| CAGR (3Y)Annualised 3-year return | -92.8% | +5.7% | +4.2% | -9.1% |
Risk & Volatility
ALKS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ALKS is the less volatile stock with a 1.00 beta — it tends to amplify market swings less than HSDT's 2.65 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 95.6% from its 52-week high vs HSDT's 0.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.65x | 1.26x | 1.00x | 1.77x |
| 52-Week HighHighest price in past year | $258.50 | $26.18 | $36.60 | $4.85 |
| 52-Week LowLowest price in past year | $1.61 | $7.53 | $25.17 | $0.80 |
| % of 52W HighCurrent price vs 52-week peak | +0.9% | +75.3% | +95.6% | +34.1% |
| RSI (14)Momentum oscillator 0–100 | 54.2 | 47.4 | 60.5 | 56.3 |
| Avg Volume (50D)Average daily shares traded | 295K | 252K | 2.2M | 2.0M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: DBVT as "Buy", ALKS as "Buy", STIM as "Buy". Consensus price targets imply 383.4% upside for STIM (target: $8) vs 31.5% for ALKS (target: $46).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $46.33 | $46.00 | $8.00 |
| # AnalystsCovering analysts | — | 15 | 28 | 7 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.5% | 0.0% |
ALKS leads in 2 of 6 categories (Profitability & Efficiency, Risk & Volatility). STIM leads in 1 (Valuation Metrics). 2 tied.
HSDT vs DBVT vs ALKS vs STIM: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is HSDT or DBVT or ALKS or STIM a better buy right now?
For growth investors, Solana Company (HSDT) is the stronger pick with 1057% revenue growth year-over-year, versus -5.
2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 5x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — HSDT or DBVT or ALKS or STIM?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +61.
7%, compared to -100. 0% for Solana Company (HSDT). Over 10 years, the gap is even starker: ALKS returned -12. 0% versus HSDT's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — HSDT or DBVT or ALKS or STIM?
By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.
00β versus Solana Company's 2. 65β — meaning HSDT is approximately 166% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 3% for Neuronetics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — HSDT or DBVT or ALKS or STIM?
By revenue growth (latest reported year), Solana Company (HSDT) is pulling ahead at 1057% versus -5.
2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Solana Company grew EPS 57. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, HSDT leads at 97. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — HSDT or DBVT or ALKS or STIM?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -679. 6% for Solana Company — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -351. 0% for HSDT. At the gross margin level — before operating expenses — HSDT leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — HSDT or DBVT or ALKS or STIM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is HSDT or DBVT or ALKS or STIM better for a retirement portfolio?
For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
00)). Solana Company (HSDT) carries a higher beta of 2. 65 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -12. 0%, HSDT: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between HSDT and DBVT and ALKS and STIM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: HSDT is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; STIM is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.